Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-08-13

Clinical Trial Update: OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD [Phase 2, Phase 3]

View source ↗

Summary

Completed Phase 2/3 trial update evaluating OROS methylphenidate (Concerta) for adult attention deficit hyperactivity disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CONCERTA (METHYLPHENIDATE HYDROCHLORIDE)

Snippet

Sponsor: University of Utah | Conditions: Attention Deficit Hyperactivity Disorder | Phase 2, Phase 3 | Status: COMPLETED